KR20160093731A - 뇌내 출혈을 치료하기 위한 조성물 및 방법 - Google Patents

뇌내 출혈을 치료하기 위한 조성물 및 방법 Download PDF

Info

Publication number
KR20160093731A
KR20160093731A KR1020167019778A KR20167019778A KR20160093731A KR 20160093731 A KR20160093731 A KR 20160093731A KR 1020167019778 A KR1020167019778 A KR 1020167019778A KR 20167019778 A KR20167019778 A KR 20167019778A KR 20160093731 A KR20160093731 A KR 20160093731A
Authority
KR
South Korea
Prior art keywords
less
ich
fxa
subject
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
KR1020167019778A
Other languages
English (en)
Korean (ko)
Inventor
스티븐 아킨
조아힘 프루비스
마커스 이. 카
서니타 헷
리마 자수자
데브라 디. 피트맨
Original Assignee
화이자 인코포레이티드
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 화이자 인코포레이티드 filed Critical 화이자 인코포레이티드
Publication of KR20160093731A publication Critical patent/KR20160093731A/ko
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21006—Coagulation factor Xa (3.4.21.6)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020167019778A 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법 Ceased KR20160093731A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201461931071P 2014-01-24 2014-01-24
US61/931,071 2014-01-24
PCT/IB2015/050313 WO2015110939A1 (en) 2014-01-24 2015-01-15 Compositions and methods for treating intracerebral hemorrhage

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020187002632A Division KR20180014221A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Publications (1)

Publication Number Publication Date
KR20160093731A true KR20160093731A (ko) 2016-08-08

Family

ID=52630418

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167019778A Ceased KR20160093731A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020217001254A Ceased KR20210008177A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020187002632A Ceased KR20180014221A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217001254A Ceased KR20210008177A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법
KR1020187002632A Ceased KR20180014221A (ko) 2014-01-24 2015-01-15 뇌내 출혈을 치료하기 위한 조성물 및 방법

Country Status (18)

Country Link
US (2) US20160375109A1 (enExample)
EP (1) EP3096779B1 (enExample)
JP (1) JP6624787B2 (enExample)
KR (3) KR20160093731A (enExample)
CN (2) CN105934250A (enExample)
AU (1) AU2015208819B2 (enExample)
BR (1) BR112016014617A2 (enExample)
CA (1) CA2937418A1 (enExample)
DK (1) DK3096779T3 (enExample)
ES (1) ES2772802T3 (enExample)
HU (1) HUE047588T4 (enExample)
IL (1) IL246637A0 (enExample)
MX (1) MX375355B (enExample)
PL (1) PL3096779T3 (enExample)
PT (1) PT3096779T (enExample)
RU (1) RU2016126423A (enExample)
SI (1) SI3096779T1 (enExample)
WO (1) WO2015110939A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1215196A1 (zh) 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法
CN112195169A (zh) 2013-09-24 2021-01-08 辉瑞大药厂 包含重组人凝血因子Xa蛋白的异质性群体的组合物
KR20260076240A (ko) 2024-11-18 2026-05-28 한림대학교 산학협력단 뇌내출혈 질환 진단용 rs5117 마커 조성물 및 이의 용도
KR20260076239A (ko) 2024-11-18 2026-05-28 한림대학교 산학협력단 뇌내출혈 질환 진단용 rs429358 마커 조성물 및 이의 용도

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06015045A (es) * 2004-06-21 2007-03-21 Novo Nordisk Healthcare Ag Uso del factor viia o equivalentes del factor viia para prevenir o atenuar el crecimiento de hemorragias y/o generacion de edemas despues de una hemorragia intracerebral.
MX336958B (es) 2005-11-15 2016-02-05 Philadelphia Children Hospital Metodos y composiciones para modular la hemostasia.
JP2011509978A (ja) * 2008-01-18 2011-03-31 ノボ ノルディスク ヘルス ケア アーゲー 選択されたＩＣＨ患者亜集団における脳内出血（ＩＣＨ）後の出血拡大、及び／又は浮腫生成の予防又は減弱のための、第ＶＩＩａ因子又は第ＶＩＩａ因子等価物の使用
EP2453910B1 (en) * 2009-07-15 2016-08-31 Portola Pharmaceuticals, Inc. Unit dose formulation of antidote for factor xa inhibitors for use in preventing bleeding
EP2467166A2 (en) * 2009-08-20 2012-06-27 CSL Behring GmbH Albumin fused coagulation factors for non-intravenous administration in the therapy and prophylactic treatment of bleeding disorders
JP6514893B2 (ja) * 2011-09-30 2019-05-15 ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ 止血を調節するための組成物および方法
KR102049900B1 (ko) * 2012-07-25 2019-11-28 카탈리스트 바이오사이언시즈, 인코포레이티드 변형 인자 x 폴리펩티드 및 이의 용도
HK1215196A1 (zh) * 2013-01-31 2016-08-19 辉瑞公司 用於抵消因子xa抑制的组合物和方法

Also Published As

Publication number Publication date
DK3096779T3 (da) 2020-02-24
BR112016014617A2 (pt) 2017-09-19
JP6624787B2 (ja) 2019-12-25
MX375355B (es) 2025-03-04
SI3096779T1 (sl) 2020-03-31
CN105934250A (zh) 2016-09-07
HUE047588T2 (hu) 2020-04-28
AU2015208819A1 (en) 2016-06-30
PT3096779T (pt) 2020-02-21
WO2015110939A1 (en) 2015-07-30
EP3096779B1 (en) 2019-12-18
US20160375109A1 (en) 2016-12-29
HUE047588T4 (hu) 2020-06-29
JP2015147764A (ja) 2015-08-20
US20190231856A1 (en) 2019-08-01
KR20210008177A (ko) 2021-01-20
PL3096779T3 (pl) 2020-05-18
IL246637A0 (en) 2016-08-31
RU2016126423A3 (enExample) 2018-03-01
EP3096779A1 (en) 2016-11-30
ES2772802T3 (es) 2020-07-08
KR20180014221A (ko) 2018-02-07
CN112156176A (zh) 2021-01-01
MX2016009665A (es) 2016-11-14
CA2937418A1 (en) 2015-07-30
RU2016126423A (ru) 2018-03-01
AU2015208819B2 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
JP2019077677A (ja) 第Ｘａ因子の阻害を中和するための組成物および方法
JP6514893B2 (ja) 止血を調節するための組成物および方法
US20190231856A1 (en) Compositions and methods for treating intracerebral hemorrhage
US20160194623A1 (en) Novel mutated tissue plasminogen activators and uses thereof
KR101672108B1 (ko) 패혈증의 치료 및/또는 개선을 위한 의약
CN113795274A (zh) 一种治疗肌萎缩侧索硬化的方法和药物
JP6629744B2 (ja) 第Ｘａ因子の半減期を延ばす組成物および方法
JP2022519327A (ja) 頭蓋内出血の治療方法及び効果の評価方法
HK40040435A (en) Compositions and methods for treating intracerebral hemorrhage
JP7237085B2 (ja) 凝固異常を伴う敗血症の治療及び／又は改善のための医薬
US20250302927A1 (en) Modified factor xa polypeptides and methods of use
HK1228257A1 (en) Compositions and methods for treating intracerebral hemorrhage
RU2818474C2 (ru) Гаптоглобин для применения в лечении неблагоприятного вторичного неврологического исхода после геморрагического инсульта
WO2026076443A1 (en) Methods for treating factor x deficiency
HK40059596A (en) Drug for treating and/or improving septicemia associated with coagulation abnormality
HK1196289B (en) Medicine for treatment and/or improvement of sepsis

Legal Events

Date Code Title Description
A201 Request for examination
PA0105 International application

Patent event date: 20160720

Patent event code: PA01051R01D

Comment text: International Patent Application

PA0201 Request for examination
PG1501 Laying open of application
E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20170804

Patent event code: PE09021S01D

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20180126

E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20180208

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20170804

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I